Heterarylpiperidine modulators of chemokine receptor activity

1. A compound of the formula I:

wherein:

R 1 is selected from the group consisting of:

(1) —CH(CH 3 ) 2 and

(2) —C(CH 3 ) 2 (OH);

R 2 is selected from the group consisting of —CH 2 -phenyl, —CH(CH 3 )-phenyl, and —C(CH 3 ) 2 -phenyl, wherein phenyl is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,

(b) trifluoromethyl,

(c) trifluoromethoxy,

(d) hydroxy,

(e) C 1-3 alkyl,

(f) —O—C 1-3 alkyl, and

(g) —CO 2 H;

R 3 is a heterocycle, wherein the heterocycle is selected from the group consisting of benzoimidazolyl, imidazolyl, indazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, tetrazolyl, thiadiazolyl, thiazolyl, triazolyl, and imidazolidinone;

wherein the heterocycle is unsubstituted or substituted with 1-5 substituents independently selected from:

(a) halo,

(b) trifluoromethyl,

(c) hydroxy,

(d) C 1-3 alkyl,

(e) —O—C 1-3 alkyl,

(f) —CO 2 R 9 ,

(g) —CN,

(h) —NR 9 R 10 , and

(i) —CONR 9 R 10 ;

R 4 , R 6 , R 9 and R 10 are H;

R 5 is selected from:

(a) hydrogen,

(b) —CH 3 , and

(c) —O—CH 3 ; and

n is the integer 1; or

a pharmaceutically acceptable salt thereof or an individual diastereomer thereof.

2. The compound of claim 1 wherein R 2 is selected from:

(1) —CH 2 -(phenyl),

(2) —CH 2 -(4-bromophenyl),

(3) —CH 2 -(3-chlorophenyl),

(4) —CH 2 -(3,5-difluorophenyl),

(5) —CH 2 -((2-trifluoromethyl)phenyl),

(6) —CH 2 -((3-trifluoromethyl)phenyl),

(7) —CH 2 -((4-trifluoromethyl)phenyl),

(8) —CH 2 -((3-trifluoromethoxy)phenyl),

(9) —CH 2 -((3-trifluoromethoxy-5-methoxy)phenyl),

(10) —CH 2 -((3,5-bis-trifluoromethyl)phenyl),

(11) —CH 2 -((3-fluoro-5-trifluoromethyl)phenyl),

(12) —CH(CH 3 )-((3,5-bis-trifluoromethyl)phenyl), and

(13) —C(CH 3 ) 2 -((3,5-bis-trifluoromethyl)phenyl).

3. The compound of claim 1 wherein R 3 is heterocycle, where the heterocycle is selected from: imidazole, pyrimidyl, triazole and tetrazole,

where the heterocycle is unsubstituted or substituted with 1-5 substituents as defined in claim 1 .

4. The compound of claim 1 wherein R 3 is heterocycle,

where the heterocycle is unsubstituted or substituted with 1-3 substituents independently selected from:

(a) halo,

(c) hydroxy,

(d) C 1-3 alkyl,

(e) —O—C 1-3 alkyl, and

(f) —CO 2 R 9 .

5. The compound of claim 1 wherein R 3 is selected from: imidazole, pyrimidyl, triazole and tetrazole.

6. The compound of claim 1 wherein R 3 is selected from:

7. The compound of claim 1 which is selected from the group consisting of the compounds below, or a pharmaceutically acceptable salt or individual diastereomer thereof:

8. A pharmaceutical composition which comprises an inert carrier and the compound of claim 1 .